Home

GARY S JACOB

CIK 1266802 · CHIEF DEVELOPMENT OFFICER · last filed 2026-08-07

GARY S JACOB is a CHIEF DEVELOPMENT OFFICER who has filed 57 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider bought $4.9K of OKYO on Aug 7, 2026. Across all open-market trades the lifetime net is +$173.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $183.9K across reported positions. 20 SEC filings were submitted jointly with SYNERGY PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$183.9K

Companies

10

Total Filings

57

Lifetime Open-Market Net

$173.1K

Filer Profile

Reported Address
C/O CALLISTO PHARMACEUTICALS INC
420 LEXINGTON AVE STE 2500
NEW YORK, NY 10170
Related Filers
SYNERGY PHARMACEUTICALS, INC. — 20 joint filings, latest 2018-06-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OKYO CHIEF DEVELOPMENT OFFICER 112,420 $1.40 $157.4K $59.8K 4 2026-08-07
Hepion Pharmaceuticals, Inc. (HEPA) Delisted Director 12 $0.08 $1 $19.9K 6 2024-02-21
Virpax Pharmaceuticals, Inc. (VRPX) Delisted Director 14 $0.00 $0 $23.8K 3 2022-01-05
CRDF Director 21,922 $1.21 $26.5K $49.7K 4 2021-06-15
Cardiff Oncology, Inc. (TROV) Delisted Director 148,954 — — $0 5 2019-06-24
Hepion Pharmaceuticals, Inc. (CTRV) Delisted Director — — — $0 2 2018-07-03
SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Executive Chairman 595,460 — — $20.0K 4 2018-06-18
Cardiff Oncology, Inc. (TROVW) Delisted Director — — — $0 7 2017-01-05
SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted Chief Executive Officer 396,999 — — $0 13 2016-06-27
CALLISTO PHARMACEUTICALS INC (KAL) Delisted Chief Executive Officer 1,474 $1.12 $1.7K $0 2 2007-10-25

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-07 OKYO Buy (P) +3,500 $4.9K EDGAR
2026-08-07 OKYO Buy (P) +3,500 $4.9K EDGAR
2026-07-23 OKYO Grant (A) +3,500 $4.9K EDGAR
2024-02-21 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) — $0 EDGAR
2022-05-19 OKYO Buy (P) +12,500 $50.0K EDGAR
2022-01-05 Virpax Pharmaceuticals, Inc. (VRPX) Delisted Grant (A) — $0 EDGAR
2021-06-15 CRDF Other (J) — $0 EDGAR
2021-05-20 Hepion Pharmaceuticals, Inc. (HEPA) Delisted Grant (A) — $0 EDGAR
2021-04-09 Virpax Pharmaceuticals, Inc. (VRPX) Delisted Grant (A) — $0 EDGAR
2021-03-23 CRDF Buy (P) +2,370 $24.7K EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.